{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:39:26Z","timestamp":1773862766439,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008456","name":"A. Alfred Taubman Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008456","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.oret.2019.01.019","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T18:09:28Z","timestamp":1549130968000},"page":"410-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Blood Pressure Is Associated with Receiving Intravitreal Anti\u2013Vascular Endothelial Growth Factor Treatment in Patients with Diabetes"],"prefix":"10.1016","volume":"3","author":[{"given":"Anjali R.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam N.","family":"Van Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Verchinina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Wichorek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-6779","authenticated-orcid":false,"given":"Dorene","family":"Markel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2019.01.019_bib1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2019.01.019_bib3","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase-III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.019_bib4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2007.06.039","article-title":"Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients","volume":"144","author":"Brown","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.019_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/eye.2014.13","article-title":"A\u00a0review of anti-VEGF agents for proliferative diabetic retinopathy","volume":"28","author":"Osaadon","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.oret.2019.01.019_bib6","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.ophtha.2016.04.004","article-title":"Predictors of diabetic macular edema treatment frequency with ranibizumab during the open-label extension of the RIDE and RISE trials","volume":"123","author":"Wykoff","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.019_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bjophthalmol-2016-309313","article-title":"The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema","volume":"101","author":"Egan","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.019_bib8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of Anti\u2013vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2019.01.019_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2017.06.029","article-title":"Baseline factors affecting changes in diabetic retinopathy severity scale score after intravitreal aflibercept or laser for diabetic macular edema","volume":"125","author":"Dhoot","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.019_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.01.019_bib11","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/bjo.83.9.1083","article-title":"Hypertension and diabetic retinopathy\u2014what\u2019s the story?","volume":"83","author":"Gillow","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.019_bib12","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1038\/s41598-017-05159-6","article-title":"Predictors of development and progression of retinopathy in patients with type 2 diabetes: importance of blood pressure parameters","volume":"7","author":"Cardoso","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2019.01.019_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The United Kingdom Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes","volume":"48","author":"King","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.oret.2019.01.019_bib14","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy","volume":"115","author":"Klein","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.019_bib15","first-page":"9898309","article-title":"Influence of age at diagnosis and time-dependent risk factors on the development of diabetic retinopathy in patients with type 1 diabetes","volume":"2016","author":"Forga","year":"2016","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.oret.2019.01.019_bib16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.01.019_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2019.01.019_bib18","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1038\/nutd.2017.30","article-title":"Glycated hemoglobin A1C and vitamin D and their association with diabetic retinopathy severity","volume":"7","author":"Long","year":"2017","journal-title":"Nutritional Diabetes"},{"key":"10.1016\/j.oret.2019.01.019_bib19","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"Ten-year follow up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.01.019_bib20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2337\/dc16-0024","article-title":"Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-on Study","volume":"39","year":"2016","journal-title":"Diabetes Care"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018305438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018305438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:25:09Z","timestamp":1762853109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653018305438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S2468653018305438"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2019.01.019","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood Pressure Is Associated with Receiving Intravitreal Anti\u2013Vascular Endothelial Growth Factor Treatment in Patients with Diabetes","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2019.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}